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in 2008, Harald Zur Hausen received the nobel Prize in 
physiology and medicine for showing that two human 
papilloma viruses, HPV16 and HPV18, were associated with the 
bulk of cervical cancers, and that some of the genes contained 
within the viruses were incorporated into the infected host 
tissue, resulting in carcinogenesis. These carcinogenic strains of 
HPV cause 70% of cervical cancer and kill an estimated 175,000 
women annually.
in 2006, the first HPV vaccine, gardasil(r), made by Merck, was 
launched on the US market, as the “first anti-cancer” vaccine. 
Subsequently, a second HPV vaccine, Cervarix(r), has been 
released by glaxoSmithKline. As with other pharmaceutical 
company products, both vaccines have been widely marketed 
and promoted by the companies. However, the marketing 
of these vaccines and the nature of the information and 
advocacy provided have led to concerns regarding the role of 
pharmaceutical companies in the dissemination of information 
relevant to consumer and public health decision making. 
in an article published in the JAMA, Rothman and Rothman 
have considered the marketing strategy for gardasil(r) and its 
implications for medical professionals (1).
in order to understand the ethical issues surrounding the 
marketing of this vaccine, it is important to understand key facts 
about HPV infection and disease and the role of these vaccines 
in prevention of cervical cancer. Essentially, HPV infections occur 
in sexually active individuals and the risk of infection increases 
with increasing partners. infection can result in no symptoms or 
a range of symptoms, from warts to cervical cancer depending 
on the virus type. The risk of cervical cancer is associated not only 
with HPV infection, but also with socio-economic status, smoking 
and other risk factors. The vaccine contains four common virus 
types, and, if given before sexual activity, prevents infection. Once 
infection has occurred, the vaccine is ineffective. in vaccine trials, 
because cervical cancer occurs several years after infection, it was 
not possible to demonstrate an actual decline in cervical cancer 
incidence, but based on the pathogenesis and natural history 
of disease it is likely that cervical cancer due to HPV 16 and 18 
will be prevented. Again, because of the length of the follow-up 
required, the studies have not been conducted to show long 
protection due to the vaccine will last.
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With these facts, Rothman and Rothman point out that the 
drug companies have adopted a multi-pronged strategy to 
promote the vaccines. Professional medical associations are 
offered educational and training grants that come with strings 
attached, where it is clear that the message to be delivered at all 
costs is to have the vaccine used as much as possible. This is, at 
least, in part to the prior experience where hepatitis B vaccine 
had little uptake for the period when it was viewed as vaccine 
for particular risk groups (2). While the lay media is known to 
fasten on to new products and present them as the panacea to 
end the disease of the moment, it is a matter of concern that 
medical scientists are being asked and encouraged to deliver 
a message that may present an unbalanced view, and where 
the emphasis on promoting the vaccine discounts key facts or 
hides information. in so doing, clarity in communication is lost-
and the public receives an incomplete message that presents 
a one-sided view of the disease and prevention of cervical 
cancer. 
There are four important ethical issues that need to be 
considered in using HPV vaccines. The first is that public 
knowledge needs to be sufficiently detailed to enable 
informed choices. The vaccine is currently being presented 
as an alternative which will remove the need for Pap smears. 
However, both vaccines contain only two types, HPV16 and 
HPV18 which cause 70% of cervical cancers and offer no 
protection against types not in the vaccine. Additionally, with 
no data on the duration of persistence of antibody response, it 
cannot be stated with certainty whether the proven protection 
from persistent infection and cervical intraepithelial neoplasia 
will result in a life-long protection from cervical cancer (3). The 
vaccines are not therapeutic, which means that women already 
infected will continue to need monitoring for early detection. 
These are important issues, but in the hype surrounding the 
vaccine, promoted by the “educational material” or Speaker 
Lecture Kit provided by companies, the authors report that 
trainers are asked to focus instead on the possibility that a 
woman infected with one type may yet benefit from protection 
against the other types (4).
The second important ethical question is regarding access to 
medical intervention, including preventive interventions such 
as vaccines. in most countries where the vaccine is available 
outside a trial setting, the mortality rates due to cervical cancer 
are low, because most women have access to and participate 
in screening which allows earlier detection and effective 
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management of the lesions. in the settings where cervical 
cancer rates and mortality are high, women have limited 
access to screening programmes (5), and most likely will not 
receive the vaccine in the near future, given the pricing models 
adopted by the companies, where cost recovery and profit must 
come before altruism. However, if low or tiered pricing were to 
be made available, a vaccination programme may, in time, be 
a more effective means of reducing the burden of disease in 
countries where the considerable resources needed in terms 
of trained personnel, laboratories and functional referral 
systems, for running screening programmes are unavailable 
or inadequate. in the marketing of these vaccines, the target 
audiences are largely in developed countries, and even within 
them, issues of healthcare disparities across ethnicity, socio-
economic status and education are not a priority. 
The third question is the role of women and the development 
of inappropriate gender stereotypes. At present the vaccine 
is to be given to female adolescents, and the implication is 
that women are responsible for issues related to reproductive 
health. This is inaccurate as both men and women are infected 
and spread the disease, although the bulk of the disease 
burden is on women.
Finally, the vaccines are to be given at adolescence. Children 
at this age should be asked for assent, and the purpose of the 
vaccine and its risks and benefits explained. This could lead 
to difficult situations, with parents being uncomfortable with 
having the vaccine discussed or worried about the vaccine 
potentially promoting unsafe sexual behaviour. However, in 
the marketing campaigns, no reference is made to the fact that 
this “anti-cancer” vaccine does not prevent sexually transmitted 
disease and no advice is offered on practising safer sex (6). 
in all of these issues and their careful consideration, 
professional medical associations have critical roles to play in 
educating their members, disseminating appropriate, balanced 
information to the public and helping to develop policy. As 
the authors highlight, in allowing themselves to latch on to 
the hype surrounding a new product without presenting a 
complete picture, the associations do themselves a profound 
disservice and diminish their role as leaders and policy makers 
for the populations they serve. To enable public trust in fair 
and well-founded research and resulting products, healthcare 
professionals and academic bodies need to act without fear 
or favour enabling appropriate decisions about the role of 
vaccines and secondary preventions programmes, particularly 
for those populations most in need of these interventions.
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